Wai Yuen Tong Medicine Holdings Limited

SEHK:897 Stock Report

Market Cap: HK$223.9m

Wai Yuen Tong Medicine Holdings Past Earnings Performance

Past criteria checks 0/6

Wai Yuen Tong Medicine Holdings's earnings have been declining at an average annual rate of -36.3%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 11.7% per year.

Key information

-36.3%

Earnings growth rate

-36.3%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate11.7%
Return on equity-0.5%
Net Margin-3.4%
Last Earnings Update31 Mar 2024

Recent past performance updates

The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business

Dec 28
The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business

Recent updates

Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too

Jul 26
Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too

Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding

Mar 11
Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding

The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business

Dec 28
The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business

Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Jul 11
Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt

Jul 05
Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt

Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Mar 08
Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now

Aug 18
Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now

Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Mar 17
Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares

Jan 22
Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares

Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Dec 16
Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Revenue & Expenses Breakdown

How Wai Yuen Tong Medicine Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:897 Revenue, expenses and earnings (HKD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24784-273540
30 Sep 231,359365440
30 Jun 231,32385440
31 Mar 23724-163370
31 Dec 221,314-985320
30 Sep 221,341-1765200
30 Jun 221,366-1435120
31 Mar 221,391-1095050
31 Dec 211,323-1224920
30 Sep 211,255-1354800
30 Jun 211,182-2554540
31 Mar 211,109-3764280
31 Dec 20979-984270
30 Sep 208491794260
30 Jun 207353094200
31 Mar 206214394150
31 Dec 196552534130
30 Sep 19689664120
30 Jun 19720714300
31 Mar 19751754490
31 Dec 18779204580
30 Sep 18807-354680
30 Jun 18826-754620
31 Mar 18846-1164560
31 Dec 17808-1064430
30 Sep 17770-964300
30 Jun 17754-944330
31 Mar 17738-934360
31 Dec 16769-874420
30 Sep 16799-814470
30 Jun 16812-284450
31 Mar 16825254430
30 Sep 158271774240
30 Jun 158291494160
31 Mar 158311214080
30 Sep 148351203840
30 Jun 148501443760
31 Mar 148651683680

Quality Earnings: 897 is currently unprofitable.

Growing Profit Margin: 897 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 897 is unprofitable, and losses have increased over the past 5 years at a rate of 36.3% per year.

Accelerating Growth: Unable to compare 897's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 897 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).


Return on Equity

High ROE: 897 has a negative Return on Equity (-0.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies